Monopar Therapeutics — Director's Dealing 2022

Jan 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2022-01-01

Reporting Person: Tsuchimoto Kim R (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-01	Common Stock	M	1231	—	Acquired	5420	Direct
2022-01-01	Common Stock	F	505	$3.21	Disposed	4915	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-01	Restricted Stock Units	$	M	1231	Disposed		Common Stock (1231)	Direct

Footnotes

F1: Represents shares acquired on vesting and settlement of restricted stock units.

F2: On January 31, 2020 the reporting person was granted 4,923 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.